These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 23075579)

  • 1. Topiramate-induced refractory hypokalemia.
    Nadkarni GN; Annapureddy N; Meisels IS
    Am J Ther; 2014; 21(5):e157-8. PubMed ID: 23075579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate and severe metabolic acidosis: case report.
    Burmeister JE; Pereira RR; Hartke EM; Kreuz M
    Arq Neuropsiquiatr; 2005 Jun; 63(2B):532-4. PubMed ID: 16059613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypokalemic periodic paralysis with topiramate.
    Fiore DM; Strober JB
    Muscle Nerve; 2011 Jan; 43(1):127-9. PubMed ID: 21171065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate and the risk of urolithiasis.
    Hanchanale VS; Biyani CS; Browning AJ; Joyce AD
    BJU Int; 2011 Feb; 107(3):352-4. PubMed ID: 21265983
    [No Abstract]   [Full Text] [Related]  

  • 5. Topiramate and metabolic acidosis: an evolving story.
    Gupta S; Gao JJ; Emmett M; Fenves AZ
    Hosp Pract (1995); 2017 Dec; 45(5):192-195. PubMed ID: 28828886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potomania as a side-effect of topiramate].
    Alda M; García Campayo J; Cerdán C; Laguna C
    Med Clin (Barc); 2007 Mar; 128(10):397-8. PubMed ID: 17386248
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversible anorgasmia with topiramate therapy for migraine.
    Newman LC; Broner SW; Lay CL
    Neurology; 2005 Oct; 65(8):1333-4. PubMed ID: 16247079
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.
    Mirza NS; Alfirevic A; Jorgensen A; Marson AG; Pirmohamed M
    Pharmacogenet Genomics; 2011 May; 21(5):297-302. PubMed ID: 21278619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic impact of topiramate on acid-base balance and potassium in childhood.
    Belotti EA; Taddeo I; Ragazzi M; Pifferini R; Simonetti GD; Bianchetti MG; Ramelli GP
    Eur J Paediatr Neurol; 2010 Sep; 14(5):445-8. PubMed ID: 20005754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of newer antiepileptic drugs.
    Racoosin JA; Knudsen JF
    JAMA; 2004 May; 291(17):2074; author reply 2074. PubMed ID: 15126428
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.
    Dell'Orto VG; Belotti EA; Goeggel-Simonetti B; Simonetti GD; Ramelli GP; Bianchetti MG; Lava SA
    Br J Clin Pharmacol; 2014 Jun; 77(6):958-64. PubMed ID: 24219102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate-induced nephrolithiasis.
    Kuo RL; Moran ME; Kim DH; Abrahams HM; White MD; Lingeman JE
    J Endourol; 2002 May; 16(4):229-31. PubMed ID: 12042105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.
    Assimos DG
    J Urol; 2014 Jun; 191(6):1810-1. PubMed ID: 25280288
    [No Abstract]   [Full Text] [Related]  

  • 14. Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase.
    Sacré A; Jouret F; Manicourt D; Devuyst O
    Nephrol Dial Transplant; 2006 Oct; 21(10):2995-6. PubMed ID: 16735391
    [No Abstract]   [Full Text] [Related]  

  • 15. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
    Winum JY; Temperini C; El Cheikh K; Innocenti A; Vullo D; Ciattini S; Montero JL; Scozzafava A; Supuran CT
    J Med Chem; 2006 Nov; 49(24):7024-31. PubMed ID: 17125255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
    Maryanoff BE; Costanzo MJ; Nortey SO; Greco MN; Shank RP; Schupsky JJ; Ortegon MP; Vaught JL
    J Med Chem; 1998 Apr; 41(8):1315-43. PubMed ID: 9548821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate increases biochemical risk of nephrolithiasis.
    Lamb EJ; Stevens PE; Nashef L
    Ann Clin Biochem; 2004 Mar; 41(Pt 2):166-9. PubMed ID: 15025812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.
    Celebisoy N; Gökçay F; Sirin H; Akyürekli O
    Acta Neurol Scand; 2007 Nov; 116(5):322-7. PubMed ID: 17922725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate for headaches.
    Evans RW; Young WB
    Headache; 2001 Sep; 41(8):833-5. PubMed ID: 11576212
    [No Abstract]   [Full Text] [Related]  

  • 20. The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex.
    Alterio V; Monti SM; Truppo E; Pedone C; Supuran CT; De Simone G
    Org Biomol Chem; 2010 Aug; 8(15):3528-33. PubMed ID: 20505865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.